参考文献
1.中华医学会糖尿病学分会. 中国 2 型糖尿病防治指南(2020 版). 中华糖尿病杂志, 2021, 13(4):315-408.
2.中华医学会糖尿病学分会. 基于胰高血糖素样肽 1 降糖药物的临床应用共识. 中华糖尿病杂志,2014,6(1):14-20.
3.王小纯, 祖向阳, 张贵星. Exendin-4 的研究进展]. 生命的化学, 2007, 27(4):334-337.
4.中华医学会内分泌学分会,中华医学会糖尿病学分会. 胰高糖素样肽-1(GLP-1)受体激动剂用于治疗 2 型糖尿病的临床专家共识. 中华内科杂志,2020,59(11):836-846.
5.American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021, 44(Suppl 1):S111-S124.
6.纪立农. 胰高血糖素样肽 1 受体激动剂周制剂中国证据与专家指导建议. 中国糖尿病杂志, 2022, 30(6):405-411.
7.Drucker DJ, Buse JB, Taylor K,et al,Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.Lancet. 2008;372(9645):1240. Epub 2008 Sep.
8.Buse JB, Rosenstock J, Sesti G,et al,Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-weekrandomised, parallel-group, multinational, open-label trial (LEAD-6).Lancet. 2009;374(9683):39. Epub 2009 Jun 8.
9.Blevins T, Pullman J, Malloy J,et al,DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.J Clin Endocrinol Metab. 2011 May;96(5):1301-10. Epub 2011.
10.Wysham C, Blevins T, Arakaki R,et al,Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).Diabetes Care. 2014 Aug;37(8):2159-67. Epub 2014 May 30.
11.Htike ZZ, Zaccardi F, Papamargaritis D,et al,Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.Diabetes Obes Metab. 2017;19(4):524. Epub 2017 Feb 17.